SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Tri Locum Partners LP

CIK 0001826434 · 287 PARK AVENUE SOUTH, 2ND FLOOR, NEW YORK, NY, 10010 · 332-232-7373

Reported Value
$219M
Q4 2023
Positions
24
Filings on Record
22
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Tri Locum Partners LP reported $219M in U.S.-listed holdings across 24 positions for Q4 2023.

Its largest position, ABBV, represents 11.9% of the portfolio.

Compared with Q3 2023, the fund opened 5 new positions and exited 42.

Portfolio Metrics

Turnover
+27.9%
vs prior filed quarter
Top-10 Concentration
+64.4%
share of reported value
Largest Position
+11.9%
Abbvie
New / Exited
5 / 42
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $275MQ4 ’20Q1 ’21: $403MQ2 ’21: $306MQ3 ’21: $252MQ3 ’21Q4 ’21: $254MQ1 ’22: $256MQ2 ’22: $244MQ2 ’22Q3 ’22: $364MQ4 ’22: $247MQ1 ’23: $328MQ1 ’23Q2 ’23: $269MQ3 ’23: $313MQ4 ’23: $219MQ4 ’23Q1 ’24: $288MQ2 ’24: $395MQ3 ’24: $417MQ3 ’24Q4 ’24: $483MQ1 ’25: $195MQ2 ’25: $330MQ2 ’25Q3 ’25: $435MQ4 ’25: $770MQ1 ’26: $713MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 67.5%ADR: 20.1%Other: 12.5%
  • Common Stock · 67.5% · $148M
  • ADR · 20.1% · $44M
  • Other · 12.5% · $27M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ASCENDIS PHARMA A/SNEW+99.5K99.5K+$13M$13M
BIIBBIOGEN INCNEW+45.8K45.8K+$12M$12M
LEGNLEGEND BIOTECH CORPNEW+102.2K102.2K+$6M$6M
PRAXPRAXIS PRECISION MEDICINES INEW+248.8K248.8K+$6M$6M
SRRKSCHOLAR ROCK HLDG CORPNEW+207.1K207.1K+$4M$4M
KVUEKENVUE INCADDED+643.8K698.8K+$14M$15M
AMGNAMGEN INCSOLD OUT−107.5K0−$29M$0
DC4DEXCOM INCSOLD OUT−267.4K0−$25M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

23 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ABBVABBVIE INChistory →COM11.89%$26M167.8K
2TEVATEVA PHARMACEUTICAL INDS LTDhistory →SPONSORED ADS8.56%$19M1.79M
3REGNREGENERON PHARMACEUTICALShistory →COM6.43%$14M16.0K
4GEHCGE HEALTHCARE TECHNOLOGIES Ihistory →COMMON STOCK6.07%$13M171.7K
5ASCENDIS PHARMA A/SSPONSORED ADR5.73%$13M99.5K
6AVADEL PHARMACEUTICALS PLCSPONSORED ADR5.42%$12M839.9K
7BIIBBIOGEN INChistory →COM5.42%$12M45.8K
8CTLTEURCATALENT INChistory →COM5.38%$12M261.8K
9AXSMAXSOME THERAPEUTICS INChistory →COM4.76%$10M130.7K
10XENEXENON PHARMACEUTICALS INChistory →COM4.75%$10M225.6K
11ARGXARGENX SEhistory →SPONSORED ADR4.21%$9M24.2K
12NTRANATERA INChistory →COM4.06%$9M141.8K
13LEGNLEGEND BIOTECH CORPhistory →SPONSORED ADS2.81%$6M102.2K
14MDGLMADRIGAL PHARMACEUTICALS INChistory →COM2.70%$6M25.5K
15VRNAVERONA PHARMA PLChistory →SPONSORED ADS2.66%$6M293.1K
16PRAXPRAXIS PRECISION MEDICINES Ihistory →COM NEW2.53%$6M248.8K
17ASTRIA THERAPEUTICS INCCOM1.91%$4M542.9K
18AZNNASTRAZENECA PLChistory →SPONSORED ADR1.81%$4M58.8K
19SRRKSCHOLAR ROCK HLDG CORPhistory →COM1.78%$4M207.1K
20ARCTARCTURUS THERAPEUTICS HLDGShistory →COM1.59%$3M110.5K
21IMMATICS N.VSHS1.33%$3M275.5K
22MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD1.31%$3M47.6K
23FEMASYS INCCOM0.02%$35,24636.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$713M17May 18, 202613F-HRchanges · EDGAR ↗
Q4 2025$770M15Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$435M18Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$330M23Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$195M22May 14, 202513F-HRchanges · EDGAR ↗
Q4 2024$483M28Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$417M20Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$395M25Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$288M27May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$219M24Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$313M61Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$269M59Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$328M47May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$247M73Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$364M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$244M51Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$256M37May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$254M41Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$252M30Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$306M31Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$403M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$275M65Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.